person · Reporting owner

Sulzberger Gabrielle

Disclosed activity across 7 companies

Tapewire entity: 10431
SEC CIK: 0001262388

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Brixmor Property Group Inc.BRX · Entity 3583	Director	June 01, 2021	June 01, 2021
ELI LILLY & CoLLY · Entity 2794	Director	September 21, 2026	September 22, 2026
Mastercard IncMA · Entity 1763	Director	June 16, 2026	June 18, 2026
TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063	Director	January 01, 2018	January 02, 2018
Warby Parker Inc.WRBY · Entity 4234	Director	June 07, 2024	June 12, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Brixmor Property Group Inc.

Report date June 01, 2021 · Filed June 01, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	37,161	Reported balance After 2021-06-01 transaction · row 1 1 source row Row 1 · 2021-06-01 · Grant · Acquired 5,000 · Balance 37,161 F1: Represents an award of restricted stock.

Filing footnotes · ownership attribution and instrument terms

F1: Represents an award of restricted stock.

ELI LILLY & Co

Report date September 21, 2026 · Filed September 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,012.4473	Reported balance After 2026-09-21 transaction · row 1 1 source row Row 1 · 2026-09-21 · Grant · Acquired 4.2565 · Balance 3,012.4473 F1: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.

Filing footnotes · ownership attribution and instrument terms

F1: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.

Mastercard Inc

Report date June 16, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	5,845	Reported balance After 2026-06-16 transaction · row 1 1 source row Row 1 · 2026-06-16 · Grant · Acquired 509 · Balance 5,845 F1: Represents deferred stock unit award that was fully vested on June 16, 2026, the date of grant, but will settle upon termination of service by the reporting person as a director.

Filing footnotes · ownership attribution and instrument terms

F1: Represents deferred stock unit award that was fully vested on June 16, 2026, the date of grant, but will settle upon termination of service by the reporting person as a director.

TEVA PHARMACEUTICAL INDUSTRIES LTD

Report date January 01, 2018 · Filed January 02, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Share UnitsSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2018-01-01 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F3: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F1: Restricted share units were granted on September 3, 2015 and vest on September 3, 2018. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Restricted Share UnitsSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2018-01-01 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F3: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4: Restricted share units were granted on May 16, 2016 and vest on May 16, 2019. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Restricted Share UnitsSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2018-01-01 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed F3: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5: Restricted share units were granted on August 11, 2017 and vest on August 11, 2020. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted share units were granted on September 3, 2015 and vest on September 3, 2018.

F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F4: Restricted share units were granted on May 16, 2016 and vest on May 16, 2019.

F5: Restricted share units were granted on August 11, 2017 and vest on August 11, 2020.

Warby Parker Inc.

Report date June 07, 2024 · Filed June 12, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	84,024	Reported balance After 2024-06-07 transaction · row 1 1 source row Row 1 · 2024-06-07 · Grant · Acquired 14,793 · Balance 84,024 F1: Represents a grant of fully-vested restricted stock units ("RSUs"), granted pursuant to the Warby Parker Inc. Amended and Restated Non-Employee Director Compensation Program. Each RSU represents a right to receive one share of Class A Common Stock. The RSUs will be settled in shares of Class A Common Stock following the earliest to occur of: (i) the director's separation from service; (ii) a change in control of the Issuer; or (iii) the director's death.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a grant of fully-vested restricted stock units ("RSUs"), granted pursuant to the Warby Parker Inc. Amended and Restated Non-Employee Director Compensation Program. Each RSU represents a right to receive one share of Class A Common Stock. The RSUs will be settled in shares of Class A Common Stock following the earliest to occur of: (i) the director's separation from service; (ii) a change in control of the Issuer; or (iii) the director's death.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Cerevel Therapeutics Holdings, Inc.

Report date August 01, 2024 · Filed August 05, 2024

Section 16 reporting ended · disclosed 2024-08-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2024-08-01 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2024-08-01 · Disposition to issuer · Disposed 48,415 · Balance 10,461 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. Row 2 · 2024-08-01 · Disposition to issuer · Disposed 10,461 · Balance 0 F2: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	0	Reported balance After 2024-08-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-08-01 · Disposition to issuer · Disposed 95,242 · Balance 0 F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest.

F2: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.

F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.

WHOLE FOODS MARKET INC

Report date August 28, 2017 · Filed August 28, 2017

Section 16 reporting ended · disclosed 2017-08-28. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2017-08-28 transaction · row 1 1 source row Row 1 · 2017-08-28 · Disposition to issuer · Disposed 52,501 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "merger agreement"), dated as of June 15, 2017, by and among Amazon.com, Inc., Walnut Merger Sub, Inc., and Whole Foods Market, Inc., shares of Whole Foods Market, Inc. common stock and restricted stock were converted into the right to receive $42.00 cash per share, without interest.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.25 · Expires 2018-05-13	Direct	Reported balance After 2017-08-28 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-08-28 · Disposition to issuer · Disposed 4,500 · Balance 0 F3: Pursuant to the merger agreement, each outstanding stock option was cancelled and converted into the right to receive an amount in cash equal to the product of (a) the number of shares subject to such option multiplied by (b) the excess, if any, of the merger consideration of $42.00 over the exercise price per share of such option. F2: The option was exercisable in four equal annual installments beginning on the first anniversary of the date on which the option was granted.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.91 · Expires 2021-05-16	Direct	Reported balance After 2017-08-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-08-28 · Disposition to issuer · Disposed 2,250 · Balance 0 F3: Pursuant to the merger agreement, each outstanding stock option was cancelled and converted into the right to receive an amount in cash equal to the product of (a) the number of shares subject to such option multiplied by (b) the excess, if any, of the merger consideration of $42.00 over the exercise price per share of such option. F2: The option was exercisable in four equal annual installments beginning on the first anniversary of the date on which the option was granted.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.30 · Expires 2023-05-13	Direct	Reported balance After 2017-08-28 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-08-28 · Disposition to issuer · Disposed 2,250 · Balance 0 F3: Pursuant to the merger agreement, each outstanding stock option was cancelled and converted into the right to receive an amount in cash equal to the product of (a) the number of shares subject to such option multiplied by (b) the excess, if any, of the merger consideration of $42.00 over the exercise price per share of such option. F2: The option was exercisable in four equal annual installments beginning on the first anniversary of the date on which the option was granted.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.99 · Expires 2024-05-19	Direct	Reported balance After 2017-08-28 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2017-08-28 · Disposition to issuer · Disposed 2,250 · Balance 0 F3: Pursuant to the merger agreement, each outstanding stock option was cancelled and converted into the right to receive an amount in cash equal to the product of (a) the number of shares subject to such option multiplied by (b) the excess, if any, of the merger consideration of $42.00 over the exercise price per share of such option. F2: The option was exercisable in four equal annual installments beginning on the first anniversary of the date on which the option was granted.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "merger agreement"), dated as of June 15, 2017, by and among Amazon.com, Inc., Walnut Merger Sub, Inc., and Whole Foods Market, Inc., shares of Whole Foods Market, Inc. common stock and restricted stock were converted into the right to receive $42.00 cash per share, without interest.

F2: The option was exercisable in four equal annual installments beginning on the first anniversary of the date on which the option was granted.

F3: Pursuant to the merger agreement, each outstanding stock option was cancelled and converted into the right to receive an amount in cash equal to the product of (a) the number of shares subject to such option multiplied by (b) the excess, if any, of the merger consideration of $42.00 over the exercise price per share of such option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 21, 2023 Filed Aug 22, 2023 20:33 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	9	$550.50	$4,954.50	Disclosure SEC source: 0000059478-23-000237 · wk-form4_1692736404.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,694 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
July 17, 2023 Filed Jul 18, 2023 20:43 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	11	$447.14	$4,918.54	Disclosure SEC source: 0000059478-23-000215 · wk-form4_1689713028.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,685 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
June 27, 2023 Filed Jun 29, 2023 21:29 UTC	Mastercard Inc MA · Entity 1763	GrantClass A Common Stock	642	$0.00	$0.00	Disclosure SEC source: 0001141391-23-000120 · wk-form4_1688074138.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,333 F1 · shares: Represents deferred stock unit award that was fully vested on June 27, 2023, the date of grant, but will be settled upon termination of the reporting person's service as a director. Read SEC document
June 20, 2023 Filed Jun 21, 2023 20:28 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	11	$451.95	$4,971.45	Disclosure SEC source: 0000059478-23-000200 · wk-form4_1687379325.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,674 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
June 08, 2023 Filed Jun 12, 2023 21:38 UTC	Warby Parker Inc. WRBY · Entity 4234	GrantClass A Common Stock	23,116	$0.00	$0.00	Disclosure SEC source: 0001104659-23-070467 · tm2318444-6_4seq1.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,231 F1 · shares: Represents a grant of fully-vested restricted stock units ("RSUs"), granted pursuant to the Warby Parker Inc. Amended and Restated Non-Employee Director Compensation Program. Each RSU represents a right to receive one share of Class A Common Stock. The RSUs will be settled in shares of Class A Common Stock following the earliest to occur of: (i) the director's separation from service; (ii) a change in control of the Issuer; (iii) the director's death; or (iv) December 7, 2027. Read SEC document
June 07, 2023 Filed Jun 9, 2023 16:51 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	GrantStock Option (Right to Buy) · Derivative	13,780	$0.00 Strike: $32.60	$0.00	Disclosure SEC source: 0000899243-23-015197 · doc4.xml · derivative · entry 2 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,780 Underlying: Common Stock · 13,780 shares Expires 2033-06-07 F3 · derivative.exercise_date: 100% of the shares subject to this option shall vest and become exercisable on the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date. Read SEC document
June 07, 2023 Filed Jun 9, 2023 16:51 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	GrantCommon Stock	3,282	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-23-015197 · doc4.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,853 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date. F1 · price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date. F2 · balance_after: On June 7, 2023, BC Perception Holdings, LP ("BC Perception") distributed an aggregate of 432,627 shares of Common Stock to certain of its limited partners (including the Reporting Person) in a pro-rata in-kind distribution to such limited partners in connection with a redemption of their partnership interests. Includes 30,301 shares of Common Stock received by the Reporting Person in the distribution described herein made in accordance with the exemptions afforded under Rule 16a-9(a) and Rule 16a-13 of the Securities Exchange Act of 1934, as amended. Read SEC document
May 15, 2023 Filed May 16, 2023 20:29 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	11	$434.51	$4,779.61	Disclosure SEC source: 0000059478-23-000180 · wf-form4_168426897503157.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,659 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
April 17, 2023 Filed Apr 19, 2023 20:33 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	13	$372.35	$4,840.55	Disclosure SEC source: 0000059478-23-000154 · wf-form4_168193637640401.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,648 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
March 20, 2023 Filed Mar 22, 2023 20:16 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	15	$333.60	$5,004.00	Disclosure SEC source: 0000059478-23-000135 · wf-form4_167951619779073.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,635 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
February 21, 2023 Filed Feb 22, 2023 21:59 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	15	$327.51	$4,912.65	Disclosure SEC source: 0000059478-23-000096 · wf-form4_167710312267960.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,614 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
January 17, 2023 Filed Jan 19, 2023 21:46 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	14	$357.74	$5,008.36	Disclosure SEC source: 0000059478-23-000014 · wf-form4_167416476756500.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,599 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
December 19, 2022 Filed Dec 20, 2022 22:15 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	28	$357.78	$10,017.84	Disclosure SEC source: 0000059478-22-000289 · wf-form4_167157454149342.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,585 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
November 21, 2022 Filed Nov 22, 2022 22:40 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	498	$361.17	$179,862.66	Disclosure SEC source: 0000059478-22-000274 · wf-form4_166915683557821.xml · nonDerivative · entry 2 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,554 Read SEC document
November 21, 2022 Filed Nov 22, 2022 22:40 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	27	$361.17	$9,751.59	Disclosure SEC source: 0000059478-22-000274 · wf-form4_166915683557821.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,056 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
October 17, 2022 Filed Oct 19, 2022 20:24 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	30	$332.76	$9,982.80	Disclosure SEC source: 0000059478-22-000245 · wf-form4_166621102231184.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,029 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
October 03, 2022 Filed Feb 14, 2023 17:47 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	GiftCommon Stock	49,624	$0.00	$0.00	Disclosure SEC source: 0000899243-23-005028 · doc5.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,270 Read SEC document
September 19, 2022 Filed Sep 21, 2022 20:47 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	33	$305.09	$10,067.97	Disclosure SEC source: 0000059478-22-000229 · wf-form4_166379325657180.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 999 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
August 15, 2022 Filed Aug 16, 2022 20:27 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	32	$313.94	$10,046.08	Disclosure SEC source: 0000059478-22-000213 · wf-form4_166068164395088.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 963 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
July 18, 2022 Filed Jul 20, 2022 00:05 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	31	$321.77	$9,974.87	Disclosure SEC source: 0000059478-22-000184 · wf-form4_165827552636440.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 931 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
June 24, 2022 Filed Jun 28, 2022 16:14 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	Exercise / conversionRestricted Stock Units · Derivative	14,270	$0.00	$0.00	Disclosure SEC source: 0000899243-22-024387 · doc4.xml · derivative · entry 2 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,270 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 14,270 RSUs vested on June 24, 2022, the third anniversary of the vesting commencement date of June 24, 2019. F2 · derivative.expiration_date: 14,270 RSUs vested on June 24, 2022, the third anniversary of the vesting commencement date of June 24, 2019. Read SEC document
June 24, 2022 Filed Jun 28, 2022 16:14 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	Exercise / conversionCommon Stock	14,270	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-024387 · doc4.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. Read SEC document
June 21, 2022 Filed Jun 22, 2022 21:31 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	33	$297.34	$9,812.22	Disclosure SEC source: 0000059478-22-000165 · wf-form4_165593349399331.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
June 21, 2022 Filed Jun 23, 2022 20:18 UTC	Mastercard Inc MA · Entity 1763	GrantClass A Common Stock	741	$0.00	$0.00	Disclosure SEC source: 0001141391-22-000123 · wf-form4_165601547188030.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,691 F1 · shares: Represents deferred stock unit award pursuant to the terms of a stockholder-approved non-employee director equity compensation plan. The award was fully vested on June 21, 2022, the date of grant, but will be settled on June 21, 2026. Read SEC document
June 14, 2022 Filed Jun 16, 2022 16:41 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	GrantStock Option (Right to Buy) · Derivative	23,459	$0.00 Strike: $24.35	$0.00	Disclosure SEC source: 0000899243-22-022826 · doc4.xml · derivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,459 Underlying: Common Stock · 23,459 shares Expires 2032-06-14 F1 · derivative.exercise_date: 100% of the shares subject to this option shall vest and become exercisable on the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date. Read SEC document
June 09, 2022 Filed Jun 14, 2022 01:01 UTC	Warby Parker Inc. WRBY · Entity 4234	GrantClass A Common Stock	16,559	$0.00	$0.00	Disclosure SEC source: 0001104659-22-070667 · tm2218339-2_4seq1.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,115 F1 · shares: Represents a grant of fully-vested restricted stock units ("RSUs"), granted pursuant to the Warby Parker Inc. Amended and Restated Non-Employee Director Compensation Program. Each RSU represents a right to receive one share of Class A Common Stock. The RSUs will be settled in shares of Class A Common Stock following the earliest to occur of: (i) the director's separation from service; (ii) a change in control of the Issuer; (iii) the director's death; or (iv) December 17, 2026. Read SEC document
May 16, 2022 Filed May 18, 2022 20:42 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	33	$299.38	$9,879.54	Disclosure SEC source: 0000059478-22-000153 · wf-form4_165290650982068.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 864 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
April 18, 2022 Filed Apr 19, 2022 20:29 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	33	$298.82	$9,861.06	Disclosure SEC source: 0000059478-22-000127 · wf-form4_165040013132753.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 831 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
March 21, 2022 Filed Mar 22, 2022 20:52 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	34	$289.64	$9,847.76	Disclosure SEC source: 0000059478-22-000104 · wf-form4_164798234545441.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 798 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
February 22, 2022 Filed Feb 24, 2022 22:09 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	41	$239.13	$9,804.33	Disclosure SEC source: 0000059478-22-000079 · wf-form4_164574055973722.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 761 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
January 18, 2022 Filed Jan 20, 2022 22:27 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	40	$247.07	$9,882.80	Disclosure SEC source: 0000059478-22-000011 · wf-form4_164271765095001.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 720 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document
November 15, 2021 Filed Nov 17, 2021 21:42 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	677	$258.43	$174,957.11	Disclosure SEC source: 0000059478-21-000218 · wf-form4_163718534875121.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 677 Read SEC document
October 04, 2021 Filed Oct 7, 2021 01:00 UTC	Warby Parker Inc. WRBY · Entity 4234	Exercise / conversionStock Option (Right to Buy) · Derivative	20,383	$0.00 Strike: $24.53	$0.00	Disclosure SEC source: 0001628280-21-019789 · wf-form4_163356843520886.xml · derivative · entry 3 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 20,383 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This stock purchase right is fully vested and will expire on November 2, 2021. F1 · derivative.expiration_date: This stock purchase right is fully vested and will expire on November 2, 2021. Read SEC document
October 04, 2021 Filed Oct 7, 2021 01:00 UTC	Warby Parker Inc. WRBY · Entity 4234	SaleClass A Common Stock	20,383	$53.52	$1,090,898.16	Disclosure SEC source: 0001628280-21-019789 · wf-form4_163356843520886.xml · nonDerivative · entry 2 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,173 Read SEC document
October 04, 2021 Filed Oct 7, 2021 01:00 UTC	Warby Parker Inc. WRBY · Entity 4234	Exercise / conversionClass A Common Stock	20,383	$24.53	$499,994.99	Disclosure SEC source: 0001628280-21-019789 · wf-form4_163356843520886.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,556 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 24, 2021 Filed Jun 24, 2021 17:32 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	Exercise / conversionRestricted Stock Units · Derivative	14,270	$0.00	$0.00	Disclosure SEC source: 0000899243-21-025758 · doc4.xml · derivative · entry 2 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,270 Underlying: Common Stock · 14,270 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 14,270 RSUs vested on June 24, 2021, the second anniversary of the vesting commencement date of June 24, 2019 (the "Vesting Commencement Date"), with the remainder vesting on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service relationship with the Issuer through each such date. F2 · derivative.expiration_date: 14,270 RSUs vested on June 24, 2021, the second anniversary of the vesting commencement date of June 24, 2019 (the "Vesting Commencement Date"), with the remainder vesting on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service relationship with the Issuer through each such date. Read SEC document
June 24, 2021 Filed Jun 24, 2021 17:32 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	Exercise / conversionCommon Stock	14,270	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-025758 · doc4.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,624 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. Read SEC document
June 22, 2021 Filed Jun 24, 2021 20:27 UTC	Mastercard Inc MA · Entity 1763	GrantClass A Common Stock	622	$0.00	$0.00	Disclosure SEC source: 0001141391-21-000132 · wf-form4_162456642280516.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,950 F1 · shares: Represents deferred stock unit award pursuant to the terms of a stockholder-approved non-employee director equity compensation plan. The award was fully vested on June 22, 2021, the date of grant, but will be settled on June 22, 2025. Read SEC document
June 17, 2021 Filed Jun 22, 2021 18:31 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	PurchaseCommon Stock	21,084	$13.06	$275,357.04	Disclosure SEC source: 0000899243-21-025352 · doc4.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,354 Read SEC document
June 10, 2021 Filed Jun 14, 2021 20:11 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	GrantStock Option (Right to Buy) · Derivative	58,003	$0.00 Strike: $13.93	$0.00	Disclosure SEC source: 0000899243-21-023721 · doc4.xml · derivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,003 Underlying: Common Stock · 58,003 shares Expires 2031-06-10 F1 · derivative.exercise_date: 100% of the shares subject to this option shall vest and become exercisable on the earlier of: (i) the one year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date. Read SEC document
June 01, 2021 Filed Jun 1, 2021 20:17 UTC	Brixmor Property Group Inc. BRX · Entity 3583	GrantCommon Stock	5,000	$0.00	$0.00	Disclosure SEC source: 0001123292-21-000927 · edgar.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,161 F1 · shares: Represents an award of restricted stock. Read SEC document
June 16, 2020 Filed Jun 18, 2020 20:10 UTC	Mastercard Inc MA · Entity 1763	GrantClass A Common Stock	707	$0.00	$0.00	Disclosure SEC source: 0001141391-20-000137 · wf-form4_159251103457108.xml · nonDerivative · entry 1 Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,328 F1 · shares: Represents deferred stock unit award pursuant to the terms of a stockholder-approved non-employee director equity compensation plan. The award was fully vested on June 16, 2020, the date of grant, but will be settled on June 16, 2024. Read SEC document
June 01, 2020 Filed Jun 1, 2020 20:07 UTC	Brixmor Property Group Inc. BRX · Entity 3583	GrantCommon Stock	5,000	$0.00	$0.00	Disclosure SEC source: 0001123292-20-000837 · edgar.xml · nonDerivative · entry 1 Greene-Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,161 F1 · shares: Represents an award of restricted stock. Read SEC document
June 25, 2019 Filed Jun 27, 2019 19:21 UTC	Mastercard Inc MA · Entity 1763	GrantClass A Common Stock	828	$0.00	$0.00	Disclosure SEC source: 0001141391-19-000114 · wf-form4_156166324519384.xml · nonDerivative · entry 1 Greene-Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,621 F1 · shares: Represents deferred stock unit award pursuant to the terms of a stockholder-approved non-employee director equity compensation plan. The award was fully vested on June 25, 2019, the date of grant, but will settle on June 25, 2023. Read SEC document
June 05, 2019 Filed Jun 5, 2019 20:13 UTC	Brixmor Property Group Inc. BRX · Entity 3583	GrantCommon Stock	5,000	$0.00	$0.00	Disclosure SEC source: 0001123292-19-000864 · edgar.xml · nonDerivative · entry 1 Greene-Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,161 F1 · shares: Represents an award of restricted stock. Read SEC document
December 03, 2018 Filed Dec 4, 2018 21:26 UTC	Mastercard Inc MA · Entity 1763	GrantClass A Common Stock	543	$0.00	$0.00	Disclosure SEC source: 0001141391-18-000143 · wf-form4_154395877713766.xml · nonDerivative · entry 1 Greene-Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 793 F1 · shares: Represents deferred stock unit award pursuant to the terms of a stockholder-approved non-employee director equity compensation plan. The award was fully vested on December 3, 2018, the date of grant, but will be settled on December 3, 2022. Read SEC document
June 05, 2018 Filed Jun 6, 2018 21:00 UTC	Brixmor Property Group Inc. BRX · Entity 3583	GrantCommon Stock	5,000	$0.00	$0.00	Disclosure SEC source: 0001123292-18-000802 · edgar.xml · nonDerivative · entry 1 Greene-Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,161 F1 · shares: Represents an award of restricted stock. Read SEC document
March 09, 2018 Filed Mar 13, 2018 21:37 UTC	Brixmor Property Group Inc. BRX · Entity 3583	PurchaseCommon Stock	750	$15.52	$11,640.00	Disclosure SEC source: 0001123292-18-000538 · edgar.xml · nonDerivative · entry 1 Greene-Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,161 Read SEC document
December 06, 2017 Filed Dec 7, 2017 22:01 UTC	Brixmor Property Group Inc. BRX · Entity 3583	PurchaseCommon Stock	1,411	$17.71	$24,988.81	Disclosure SEC source: 0001123292-17-001747 · edgar.xml · nonDerivative · entry 1 Greene-Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,411 Read SEC document
August 28, 2017 Filed Aug 28, 2017 16:57 UTC	WHOLE FOODS MARKET INC WFM · Entity 173568	Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative	2,250	Not disclosed Strike: $35.99	Not disclosed	Disclosure SEC source: 0000865436-17-000215 · wf-form4_150395385122737.xml · derivative · entry 5 Greene-Sulzberger Gabrielle · CIK 0001262388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2024-05-19 F3 · price: Pursuant to the merger agreement, each outstanding stock option was cancelled and converted into the right to receive an amount in cash equal to the product of (a) the number of shares subject to such option multiplied by (b) the excess, if any, of the merger consideration of $42.00 over the exercise price per share of such option. F2 · derivative.exercise_date: The option was exercisable in four equal annual installments beginning on the first anniversary of the date on which the option was granted. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.